Afatinib for Treating Advanced Squamous Non-Small-Cell Lung Cancer after Platinum-based Chemotherapy (Terminated Appraisal) (TA444)

Technology Appraisal Guidance No. 444

Source: National Institute for Health and Care Excellence

NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from Boehringer Ingelheim. We will review this decision if the company decides to make a submission.

A copy of the full document and background is available on the Internet at 

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: [email protected]

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal).
Issue Date: May 2017

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

intelog app

Access the full drug database and quick-reference tables on the go

Find out more